Goldman Sachs Raises TG Therapeutics, Inc. (TGTX) Target to $39 on 2026 Guidance
On January 15, Goldman Sachs raised its price target on TG Therapeutics, Inc. (NASDAQ:TGTX) to $39 from $37 while maintaining a Neutral rating.
Tg Therapeutics Inc. (TGTX)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Soleus Capital Guy Levy | 3,139,312 | $93,582,891 | -19% | 3.45% |
| 2. | Hood River Capital Management David Swank | 1,581,234 | $47,136,586 | +2% | 0.52% |
| 3. | Citadel Investment Group Ken Griffin | 1,011,037 | $30,139,013 | +2% | 0% |
| 4. | GLG Partners Noam Gottesman | 956,637 | $28,517,349 | -6% | 0.05% |
| 5. | Squarepoint Ops LLC Maxime Fortin (Cio) | 852,522 | $25,413,681 | +69% | 0.03% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $10.13 | 100,000 | $1,013,000.00 | 12,073,021 | 2023-08-11 | Filing | |
| $10.64 | 9,000 | $95,760.00 | 201,848 | 2023-01-06 | Filing | |
| $7.04 | 50,000 | $351,750.00 | 12,878,185 | 2019-06-26 | Filing | |
| $6.53 | 114,855 | $750,003.15 | 5,114,855 | 2015-02-17 | Filing | |
| $3.43 | 10,000 | $34,300.00 | 7,839,471 | 2013-12-11 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $32.57 | 5,000 | $162,850.00 | 223,816 | 2025-11-24 | Filing | |
| $32.24 | 20,852 | $672,268.48 | 94,061 | 2025-09-11 | Filing | |
| $36.94 | 10,000 | $369,400.00 | 228,816 | 2025-06-13 | Filing | |
| $28.53 | 10,021 | $285,939.21 | 660,611 | 2025-01-06 | Filing | |
| $30.29 | 11,337 | $343,443.08 | 670,632 | 2025-01-03 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 21,848,462 | $651,302,651 | 0.01% | |
| 2. | 15,841,002 | $472,220,271 | 0.01% | |
| 3. | 8,479,999 | $252,788,770 | 0.01% | |
| 4. | 3,448,033 | $102,785,853 | 0.08% | |
| 5. | 3,403,866 | $101,482,782 | 0.01% |
News See All
10 Best Long Term Healthcare Stocks to Buy
Investing in healthcare stocks offers a combination of defensive stability and long-term growth potential, supported by consistent demand for medical services, pharmaceuticals, and healthcare technologies...
TG Therapeutics (TGTX) Sees Price Target Drop from JPMorgan
On February 2, JPMorgan analyst Brian Cheng reduced the price target on TG Therapeutics (NASDAQ:TGTX) to $46 from $49 while maintaining the Overweight rating on the shares.
13 Best Revenue Growth Stocks to Buy Right Now
Speaking to CNBC on January 13, Ari Wald, Head of Technical Analysis at Oppenheimer, said U.S.
TG Therapeutics, Inc. (NASDAQ:TGTX) Q3 2025 Earnings Call Transcript
Operator: Greetings, and welcome to the TG Therapeutics' Third Quarter Earnings Call and Webcast. [Operator Instructions] Please note, this conference is being recorded.
TG Therapeutics, Inc. (NASDAQ:TGTX) Q2 2025 Earnings Call Transcript
Operator: Greetings. Welcome to TG Therapeutics' Second Quarter Earnings Call and Webcast. [Operator Instructions] Please note, this conference is being recorded.
TG Therapeutics (TGTX) Slashes 18% on Lower 2025 Sales Guidance
In a statement, TG Therapeutics, Inc. (NASDAQ:TGTX) raised its revenue outlook for Briumvi to a range of $570 million to $575 million from the $560 million previously, but was still lower than the $596...
14 Stocks Jim Cramer Recently Looked At
“Who is powering this market higher?... I think it's the young people, people who are part of the great wealth transfer... They have the money now, and they invest differently from the older folks.
10 Best Cancer Stocks to Invest in for Long-Term Gains
After cardiovascular disease, cancer is the second most common cause of mortality worldwide.
TG Therapeutics, Inc. (NASDAQ:TGTX) Q1 2025 Earnings Call Transcript
Operator: Greetings, and welcome to TG Therapeutics First Quarter Conference Call and Webcast. At this time, all participants are in a listen-only mode.
Hedge Fund Resource Center